John Routsias

Prof. John Routsias

School of Medicine, National and Kapodistrian University of Athens, Athens, Attikí, Greece
orcid

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2004 in Journal of Bone and Mineral Research
Verified
Journal Article
Closed access
PDF file
Meropi KontogianniMeropi Kontogianni
Meropi Kontogianni
UDUrania G Dafni
Urania G Dafni
JRJohn Routsias
John Routsias
FSFotini N. Skopouli
Fotini N. Skopouli
Fat mass is a predictor of BMD; however, the mechanisms involved remain uncertain. Two adipokines, leptin and adiponectin, were examined as potential mediators of this relation in 80 perimenopausal women. Adiponectin did not exert any effect on BMD, whereas leptin exerted a negative one, with insulin acting as a confounder to this relation. Introduction: Fat mass is an important determinant of bone density, but the mechanism involved in this relation is uncertain. Leptin and adiponectin, as circulating peptides of adipocyte origin, are potential contributors to this relation. We investigated the role of leptin and adiponectin in mediating fat mass effects on the skeleton of perimenopausal women. Materials and Methods: Twenty-five premenopausal and 55 postmenopausal, healthy women (42–68 years old) participated in our study. Lumbar spine BMD (BMDL2-L4) and total body BMC (TBBMC) were measured with DXA, leptin levels with ELISA, and adiponectin levels with radioimmunoassay (RIA). Additionally, body composition analysis was performed, as well as measurements of several hormones. Results: It was shown that serum leptin levels were negatively correlated with BMD (β = −0.005, p = 0.027) and TBBMC (β = −14.32, p = 0.013). The above correlation was observed only when serum insulin levels were included, as an independent variable, in the regression analysis model. Adiponectin was not significantly correlated with BMDL2-L4 nor with TBBMC, either in the presence or absence of insulin. Conclusion: Circulating adiponectin does not seem to exert any effect on bone mass. In contrast, circulating leptin showed a negative correlation with bone mass, dependent on serum insulin levels.

14 April 2015 in Clinical and Experimental Immunology
Verified
Journal Article
Closed access
PDF file
CSChrysanthi Skevaki
Chrysanthi Skevaki
MPMichail Pararas
Michail Pararas
KKKalliopi Kostelidou
Kalliopi Kostelidou
Athanasios TsakrisAthanasios Tsakris
Athanasios Tsakris
JRJohn Routsias
John Routsias

1 May 2006 in Journal of Autoimmunity
Verified
Journal Article
Closed access
AGAndreas Goules
Andreas Goules
ATAthanasios G. Tzioufas
Athanasios G. Tzioufas
MMMenelaos N. Manousakis
Menelaos N. Manousakis
KKKyriakos A. Kirou
Kyriakos A. Kirou
MCMary K. Crow
Mary K. Crow
JRJohn Routsias
John Routsias

21 January 2010 in Blood
Verified
Journal Article
Closed access
PDF file
MSMarina P. Sikara
Marina P. Sikara
JRJohn Routsias
John Routsias
MSMartina Samiotaki
Martina Samiotaki
GPGeorge Panayotou
George Panayotou
HMHaralampos M. Moutsopoulos
Haralampos M. Moutsopoulos
PVPanayiotis G. Vlachoyiannopoulos
Panayiotis G. Vlachoyiannopoulos
Antiphospholipid syndrome (APS) is an autoimmune thrombophilia characterized by arterial/venous thrombosis and/or pregnancy morbidity in the presence of antiphospholipid antibodies that mainly recognize β2 glycoprotein I (β2GPI). To investigate potential platelet ligands of β2GPI, platelet membrane proteins from healthy persons and patients with APS were passed through a β2GPI-affinity column. By using mass spectrometry, platelet factor 4 (PF4) appeared as the dominant β2GPI binding protein. PF4 could bind in vitro, with high-affinity, recombinant β2GPI, and the binding was abrogated by soluble β2GPI. Coprecipitation experiments further confirmed this interaction. In silico molecular docking showed that PF4 tetramers can bind 2 β2GPI molecules simultaneously. Size exclusion chromatography confirmed that anti-β2GPI antibodies selectively interact with complexes composed of (β2GPI)2–(PF4)4. In addition, as shown by the β2GPI antigenicity evaluation, the reactivity of APS sera was higher against PF4–β2GPI complex than against β2GPI alone. On complex formation, anti-β2GPI–β2GPI–PF4 significantly induced platelet p38MAPK phosphorylation and TXB2 production, mainly through F(ab′)2 fragments of antibodies. In summary, this study makes evident that β2GPI forms stable complexes with PF4, leading to the stabilization of β2GPI dimeric structure that facilitates the antibody recognition. This interaction can probably be involved in the procoagulant tendency of APS.

26 September 2007 in Clinical Reviews in Allergy & Immunology
Verified
Journal Article
Closed access
PDF file
JRJohn Routsias
John Routsias
ATAthanasios G. Tzioufas
Athanasios G. Tzioufas

1 May 2011 in Clinical Ophthalmology
Verified
Journal Article
Open access
PDF file
SISinapis
Sinapis
CSChristos I. Sinapis
Christos I. Sinapis
DSDimitrios I. Sinapis
Dimitrios I. Sinapis
JRJohn Routsias
John Routsias
APAlkistis Pantopoulou
Alkistis Pantopoulou
STStamatis E Theocharis
Stamatis E Theocharis
Purpose: To describe the pharmacokinetics of intravitreal bevacizumab (Avastin®) in rabbits. Methods: The right eye of 20 rabbits was injected intravitreally with 1.25 mg/0.05 mL bevacizumab. Both eyes of four rabbits each time were enucleated at days 1, 3, 8, 15, and 29. Bevacizumab concentrations were measured in serum, aqueous humor, and vitreous. Results: Maximum vitreous (406.25 µg/mL) and aqueous humor (5.83 µg/mL) concentrations of bevacizumab in the right eye were measured at day 1. Serum bevacizumab concentration peaked at day 8 (0.413 µg/mL) and declined to 0.032 µg/mL at 4 weeks. Half-life values in right vitreous, right aqueous humor, and serum were 6.61, 6.51, and 5.87 days, respectively. Concentration of bevacizumab in the vitreous of the noninjected eye peaked at day 8 (0.335 ng/mL) and declined to 0.218 ng/mL at 4 weeks. In the aqueous humor of the noninjected eye, maximum concentration of bevacizumab was achieved at day 8 (1.6125 ng/mL) and declined (to 0.11 ng/mL) at 4 weeks. Conclusion: The vitreous half-life of 1.25 mg/0.05 mL intravitreal bevacizumab was 6.61 days in this rabbit model. Maximum concentrations of bevacizumab were reached at day 1 in both vitreous and aqueous humor of the right eye and at day 8 in the serum. Very low concentrations of bevacizumab were measured in the fellow noninjected eye.